KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Dynavax Technologies (DVAX) over the last 2 years, with Mar 2011 value amounting to $65.5 million.

  • Dynavax Technologies' Cash & Equivalents rose 34.29% to $160.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.2 million, marking a year-over-year increase of 34.29%. This contributed to the annual value of $95.9 million for FY2024, which is 36.20% down from last year.
  • Latest data reveals that Dynavax Technologies reported Cash & Equivalents of $160.2 million as of Q3 2025, which was up 61.70% from $99.1 million recorded in Q2 2025.
  • In the past 5 years, Dynavax Technologies' Cash & Equivalents registered a high of $436.2 million during Q4 2021, and its lowest value of $51.7 million during Q1 2025.
  • For the 3-year period, Dynavax Technologies' Cash & Equivalents averaged around $134.3 million, with its median value being $132.0 million (2024).
  • The largest annual percentage gain for Dynavax Technologies' Revenue - Interest and Investment Income in the last 5 years was 66.93% (2010), contrasted with its biggest fall of 43.33% (2010).
  • Dynavax Technologies' Revenue - Interest and Investment Income (Quarterly) stood at $50.5 million in 2009, then surged by 66.93% to $84.2 million in 2010, then skyrocketed by 47.92% to $65.5 million in 2011.
  • Its Cash & Equivalents was $160.2 million in Q3 2025, compared to $99.1 million in Q2 2025 and $51.7 million in Q1 2025.